Table_1_Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?.xlsx

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the pandemic Coronavirus Disease 2019 (COVID-19). This virus is highly transmissible among individuals through both droplets and aerosol leading to determine severe pneumonia. Among the various factors that can influence both the onset of disease and the severity of its complications, the microbiome composition has also been investigated. Recent evidence showed the possible relationship between gut, lung, nasopharyngeal, or oral microbiome and COVID-19, but very little is known about it. Therefore, we aimed to verify the relationships between nasopharyngeal microbiome and the development of either COVID-19 or the severity of symptoms. To this purpose, we analyzed, by next generation sequencing, the hypervariable V1-V2-V3 regions of the bacterial 16S rRNA in nasopharyngeal swabs from SARS-CoV-2 infected patients (n=18) and control (CO) individuals (n=12) using Microbiota solution A (Arrow Diagnostics). We found a significant lower abundance of Proteobacteria and Fusobacteria in COVID-19 patients in respect to CO (p=0.003 and p

严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引发了全球性的新型冠状病毒肺炎（COVID-19）大流行。该病毒通过飞沫和气溶胶在个体间高度传染，导致重症肺炎。在众多可能影响疾病发病和并发症严重程度的因素中，微生物群组成也受到了研究。近期的研究证据显示，肠道、肺、鼻咽部或口腔微生物群与COVID-19之间可能存在关联，但对于这一领域的了解尚属有限。因此，本研究旨在验证鼻咽部微生物群与COVID-19发病或症状严重程度之间的关系。为此，我们利用下一代测序技术，分析了SARS-CoV-2感染患者（n=18）和控制个体（n=12）鼻咽拭子中细菌16S rRNA的超变区V1-V2-V3区域，采用Microbiota溶液A（Arrow Diagnostics）。我们发现，与控制组相比，COVID-19患者的变形菌和梭杆菌丰度显著降低（p=0.003和p=0.004）。